Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.98 USD

16.98
6,213,790

+0.17 (1.01%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $16.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

Manaswita Ghosh Dutta headshot

3 Best Drugmakers That Are Immune to Coronavirus Fright

The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize

Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.

Teva (TEVA) Q4 Earnings In Line, Sales Beat, Stock Up

Teva Pharmaceutical (TEVA) matches earnings estimates but beats the same for sales. Shares rise in pre-market trading.

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $12.10, moving +0.33% from the previous trading session.

Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal

Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.

Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe

Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study

Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.

Indrajit Bandyopadhyay headshot

Will J&J be Able to Overcome Its Legal Troubles in 2020?

Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?

As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.

Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $9.97, moving +1.73% from the previous trading session.

Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

Kinjel Shah headshot

Fed Reportedly Opens Criminal Investigation on Opioid Makers

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.